The Morning Brief Corner office Conversation with Nandini Piramal of Piramal Pharma, and Arjun Juneja of Mankind Pharma
Nov 24, 2025
Nandini Piramal, Chairperson of Piramal Pharma, and Arjun Juneja, COO of Mankind Pharma, delve into the future of India's pharmaceutical industry. They discuss Piramal's transformation focusing on CDMO and hospital generics, and Mankind's journey to innovation in obesity treatment. Topics include the importance of quality in manufacturing, the challenges of global regulatory scrutiny, and the need for a quality-first culture. They emphasize strategic partnerships and share ambitious visions for 2047, aiming for leadership in the evolving pharma landscape.
AI Snips
Chapters
Transcript
Episode notes
Scale And Culture Drove India's Pharma Rise
- Indian pharma scaled from about $3bn in 1990 to $60bn today, driving a very different industry landscape.
- Nandini Piramal says culture and scale were central to that transformation and global expansion.
Growing Up With A Founder’s Grit
- Arjun Juneja recounts watching his father's journey from 1995, learning through lean patches and tough periods.
- He credits Mankind's rise to learning, adapting, and moving from smaller towns to larger markets and specialty areas.
Choose Where You Can Be Category Leader
- After selling its domestic business in 2010 Piramal focused on CDMO, complex hospital generics, and OTC.
- Nandini Piramal explains they doubled down where they could be one or two leaders and exited non-core, under‑scale areas.